Literature DB >> 16464398

Update on hereditary breast cancer.

Karen Lisa Smith1, Mark E Robson.   

Abstract

Women with BRCA1 or BRCA2 mutations are at substantial risk for breast and ovarian cancer. This review describes recent developments in the approach to hereditary breast cancer. Risk-reducing surgeries remain the most effective means of preventing breast cancer in mutation carriers. For women with breast tissue at risk, magnetic resonance imaging is rapidly becoming incorporated into screening programs. For affected women, management does not currently differ from that of women with sporadic breast cancer, although women may choose to undergo bilateral mastectomy. Preclinical data suggest that BRCA mutation-associated breast cancers may benefit from specific targeted therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464398     DOI: 10.1007/s11912-006-0004-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  49 in total

1.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Steven A Narod; Marie-Pierre Dubé; Jan Klijn; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; Diane Provencher; Ketil Heimdal; Pal Moller; Mark Robson; Kenneth Offit; Claudine Isaacs; Barbara Weber; Eitan Friedman; Ruth Gershoni-Baruch; Gad Rennert; Barbara Pasini; Theresa Wagner; Mary Daly; Judy E Garber; Susan L Neuhausen; Peter Ainsworth; Hakan Olsson; Gareth Evans; Michael Osborne; Fergus Couch; William D Foulkes; Ellen Warner; Charmaine Kim-Sing; Olufunmilayo Olopade; Nadine Tung; Howard M Saal; Jeffrey Weitzel; Sofia Merajver; Marion Gauthier-Villars; Helena Jernstrom; Ping Sun; Jean-Sebastien Brunet
Journal:  J Natl Cancer Inst       Date:  2002-12-04       Impact factor: 13.506

2.  Breast MRI for women with hereditary cancer risk.

Authors:  Mark E Robson; Kenneth Offit
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

3.  Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.

Authors:  D G R Evans; F Lalloo; P Hopwood; A Maurice; A Baildam; A Brain; L Barr; A Howell
Journal:  Eur J Surg Oncol       Date:  2005-07-07       Impact factor: 4.424

4.  Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.

Authors:  Roger L Milne; Julia A Knight; Esther M John; Gillian S Dite; Ronald Balbuena; Argyrios Ziogas; Irene L Andrulis; Dee W West; Frederick P Li; Melissa C Southey; Graham G Giles; Margaret R E McCredie; John L Hopper; Alice S Whittemore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

5.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

6.  Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.

Authors:  Mark Robson; Tiffany Svahn; Beryl McCormick; Patrick Borgen; Clifford A Hudis; Larry Norton; Kenneth Offit
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

7.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

8.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.

Authors:  Madeleine Tilanus-Linthorst; Leon Verhoog; Inge-Marie Obdeijn; Karina Bartels; Marian Menke-Pluymers; Alexander Eggermont; Jan Klijn; Hanne Meijers-Heijboer; Theo van der Kwast; Cecile Brekelmans
Journal:  Int J Cancer       Date:  2002-11-01       Impact factor: 7.396

Review 10.  The role of BRCA1 in the cellular response to chemotherapy.

Authors:  Richard D Kennedy; Jennifer E Quinn; Paul B Mullan; Patrick G Johnston; D Paul Harkin
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

View more
  4 in total

1.  BRCA1/2 test results impact risk management attitudes, intentions, and uptake.

Authors:  Suzanne C O'Neill; Heiddis B Valdimarsdottir; Tiffani A Demarco; Beth N Peshkin; Kristi D Graves; Karen Brown; Karen E Hurley; Claudine Isaacs; Sharon Hecker; Marc D Schwartz
Journal:  Breast Cancer Res Treat       Date:  2010-04-10       Impact factor: 4.872

2.  Continuing medical education and maintenance of certification: essential links.

Authors:  Eric S Holmboe; Christine Cassel
Journal:  Perm J       Date:  2007

3.  Self administered screening for hereditary cancers in conjunction with mammography and ultrasound.

Authors:  Charles H McDonnell; David J Seidenwurm; Diana E McDonnell; Kristie A Bobolis
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

4.  Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction.

Authors:  Marc D Schwartz; Heiddis B Valdimarsdottir; Tiffani A DeMarco; Beth N Peshkin; William Lawrence; Jessica Rispoli; Karen Brown; Claudine Isaacs; Suzanne O'Neill; Rebecca Shelby; Sherry C Grumet; Margaret M McGovern; Sarah Garnett; Heather Bremer; Suzanne Leaman; Kathryn O'Mara; Sarah Kelleher; Kathryn Komaridis
Journal:  Health Psychol       Date:  2009-01       Impact factor: 4.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.